New Clinical Aspects of Eplerenone Use in Clinical Practice
The problem of the discrepancy between convincing evidences of the effectiveness of the use of mineralocorticoid receptor antagonists in patients with heart failure with reduced left ventricular ejection fraction and insufficiently frequent their use in clinical practice for the treatment of these p...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Столичная издательская компания
2018-09-01
|
| Series: | Рациональная фармакотерапия в кардиологии |
| Subjects: | |
| Online Access: | https://www.rpcardio.online/jour/article/view/1733 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849227646849777664 |
|---|---|
| author | S. R. Gilyarevskiy N. G. Bendeliani M. V. Golshmid I. M. Kuzmina |
| author_facet | S. R. Gilyarevskiy N. G. Bendeliani M. V. Golshmid I. M. Kuzmina |
| author_sort | S. R. Gilyarevskiy |
| collection | DOAJ |
| description | The problem of the discrepancy between convincing evidences of the effectiveness of the use of mineralocorticoid receptor antagonists in patients with heart failure with reduced left ventricular ejection fraction and insufficiently frequent their use in clinical practice for the treatment of these patients is considered in the article. Experts opinions on the reasons for this discrepancy are also presented. New data on the effectiveness of the use of the mineralocorticoid receptor antagonist, eplerenone, in some clinical situations identified in the analysis of subgroups of participants in a large randomized clinical trial EMPHASIS-HF are discussed. The main goal of this study was to evaluate the efficacy of eplerenone compared with placebo in patients with heart failure and reduced left ventricular function. In addition, experimental animal studies, which may indicate the pleiotropic effects of eplerenone in patients with vascular diseases, are presented. The new data on the effectiveness of eplerenone in subgroups of patients with heart failure and certain characteristics may be an additional reason to draw the attention of physicians to the benefits of its use and, accordingly, its more frequent application in clinical practice for the treatment of patients with clear indications for this therapy. |
| format | Article |
| id | doaj-art-4c333d0c852447b9af9366bd8917d22b |
| institution | Kabale University |
| issn | 1819-6446 2225-3653 |
| language | English |
| publishDate | 2018-09-01 |
| publisher | Столичная издательская компания |
| record_format | Article |
| series | Рациональная фармакотерапия в кардиологии |
| spelling | doaj-art-4c333d0c852447b9af9366bd8917d22b2025-08-23T10:00:30ZengСтоличная издательская компанияРациональная фармакотерапия в кардиологии1819-64462225-36532018-09-0114461262010.20996/1819-6446-2018-14-4-612-6201515New Clinical Aspects of Eplerenone Use in Clinical PracticeS. R. Gilyarevskiy0N. G. Bendeliani1M. V. Golshmid2I. M. Kuzmina3Russian Medical Academy of Continuing Professional EducationA.N. Bakulev National Medical Research Center of Cardiovascular SurgeryRussian Medical Academy of Continuing Professional EducationSklifosovsky Research Institute of Emergency MedicineThe problem of the discrepancy between convincing evidences of the effectiveness of the use of mineralocorticoid receptor antagonists in patients with heart failure with reduced left ventricular ejection fraction and insufficiently frequent their use in clinical practice for the treatment of these patients is considered in the article. Experts opinions on the reasons for this discrepancy are also presented. New data on the effectiveness of the use of the mineralocorticoid receptor antagonist, eplerenone, in some clinical situations identified in the analysis of subgroups of participants in a large randomized clinical trial EMPHASIS-HF are discussed. The main goal of this study was to evaluate the efficacy of eplerenone compared with placebo in patients with heart failure and reduced left ventricular function. In addition, experimental animal studies, which may indicate the pleiotropic effects of eplerenone in patients with vascular diseases, are presented. The new data on the effectiveness of eplerenone in subgroups of patients with heart failure and certain characteristics may be an additional reason to draw the attention of physicians to the benefits of its use and, accordingly, its more frequent application in clinical practice for the treatment of patients with clear indications for this therapy.https://www.rpcardio.online/jour/article/view/1733heart failureeplerenonerandomized clinical trialclinical practice |
| spellingShingle | S. R. Gilyarevskiy N. G. Bendeliani M. V. Golshmid I. M. Kuzmina New Clinical Aspects of Eplerenone Use in Clinical Practice Рациональная фармакотерапия в кардиологии heart failure eplerenone randomized clinical trial clinical practice |
| title | New Clinical Aspects of Eplerenone Use in Clinical Practice |
| title_full | New Clinical Aspects of Eplerenone Use in Clinical Practice |
| title_fullStr | New Clinical Aspects of Eplerenone Use in Clinical Practice |
| title_full_unstemmed | New Clinical Aspects of Eplerenone Use in Clinical Practice |
| title_short | New Clinical Aspects of Eplerenone Use in Clinical Practice |
| title_sort | new clinical aspects of eplerenone use in clinical practice |
| topic | heart failure eplerenone randomized clinical trial clinical practice |
| url | https://www.rpcardio.online/jour/article/view/1733 |
| work_keys_str_mv | AT srgilyarevskiy newclinicalaspectsofeplerenoneuseinclinicalpractice AT ngbendeliani newclinicalaspectsofeplerenoneuseinclinicalpractice AT mvgolshmid newclinicalaspectsofeplerenoneuseinclinicalpractice AT imkuzmina newclinicalaspectsofeplerenoneuseinclinicalpractice |